Showing 7141-7150 of 9747 results for "".
- Layoffs at Medicis top 300, with 117 staffers chosen to stayhttps://practicaldermatology.com/news/20130104-layoffs_at_medicis_top_300_with_117_staffers_chosen_to_stay/2459648/The layoff toll at Medicis Pharmaceutical has topped 300, the Phoenix Business Journal reports. Valeant Pharmaceuticals ($VRX), which wrapped up its buyout of the Arizona-based skin drug company last week, has cut 319 staffers--and kept 117--as it integrates Medicis into its own dermatology operatio
- Promius Pharma, LLC Increases Sales Force by 50 Percenthttps://practicaldermatology.com/news/20130102-promius_pharma_llc_increases_sales_force_by_50_percent/2459650/Promius Pharma, LLC is expanding its sales force to 60 from 40. Promius Pharma, which markets clinical prescription products to the US dermatology community, is in growth mode according to Rob D'Urso, head of sales and marketing for the company. “Promius Pharma is gearing up for significant growth
- Allergan Acquires SkinMedicahttps://practicaldermatology.com/news/20121221-allergan_acquires_skinmedica/2459654/Allergan, Inc. completed the acquisition of SkinMedica, Inc. Under the terms of the agreement, which was first announced on November 16, 2012, Allergan paid approximately $350 million (subject to certain adjustments) for the business, which inclu
- Glytone Announces Antioxidant Kit Specialhttps://practicaldermatology.com/news/20121217-glytone_announces_antioxidant_kit_special/2459657/Glytone currently offers two limited-edition antioxidant kits, featuring a selection of three products from the Glytone antioxidant range. One version includes Anti-aging Serum, Anti-aging Cream, and Anti-aging Eye Cream while the other featur
- Galderma Acquires Spirighttps://practicaldermatology.com/news/20121213-galderma_acquires_spirig/2459659/Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading br
- Murad Names Suzanne Dawson Chief Marketing Officerhttps://practicaldermatology.com/news/20121213-murad_names_suzanne_dawson_chief_marketing_officer/2459658/Murad Inc. named Suzanne Dawson Chief Marketing Officer, overseeing all global marketing including brand development, advertising, public relations, creative, and education, for products, services, and new market opportunities. Dawson comes to Murad
- AD RescueWear Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/20121204-ad_rescuewear_receives_nea_seal_of_acceptance/2459662/The National Eczema Association Seal of Acceptance was awarded to AD RescueWear for its use by patients with eczema or severe sensitive skin conditions. AD RescueWear manufactures and sells ready-made, wet wrap therapy products for the treatment
- Wells Fargo Practice Finance Helps Practices Affected by Hurricane Sandyhttps://practicaldermatology.com/news/20121204-wells_fargo_practice_finance_helps_practices_affected_by_hurricane_sandy/2459663/As the northeastern United States recovers from the effects of Hurricane Sandy, Wells Fargo Practice Finance will donate disaster relief funds to the American Dental Association Foundation and other member organizations. Existin
- ARTAS System Adopted by Minneapolis Surgeonhttps://practicaldermatology.com/news/20121204-artas_system_adopted_by_minneapolis_surgeon/2459664/Restoration Robotics, Inc. announced the first use of its revolutionary ARTAS System in Minneapolis by Dr. Ron Shapiro of Shapiro Medical Group. The ARTAS System is the first and only FDA-cleared, physician-controlled, computer-assisted technolo
- Court: Off-label Drug Promotion Is Protected Speechhttps://practicaldermatology.com/news/20121204-court_off-label_drug_promotion_is_protected_speech/2459665/The 2nd US Circuit Court of Appeals in New York voted 2-1 to overturn a pharmaceutical salesman's conviction for off-label drug marketing, citing violations against his free speech rights under the First Amendment. The ruling could threaten FDA rules that prevent the marketing of treatments for uses